AB Science reports mixed results for its phase 3 clinical trial
AB Science confirms the duration of its phase 3 trial for its ALS treatment but struggles to convince investors.
Published 2sem1 sourceImportantupdated 4j
Lire en français
≈ 21s
The fact
The clinical trial, ongoing since 2025, elicits mixed reactions among shareholders.
The stock price drops 8% during the session following the announcement.
Click the link to read an article on the topic: